The malignant ascites pipeline possesses only two drugs in mid-stage developments to be approved in the near future. The major key players include Clover Biopharmaceuticals and Wuhan YZY Biopharma which hold the potential to create a significant positive shift in the malignant ascites…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.